{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:27:21Z","timestamp":1791649641378,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031A423A"],"award-info":[{"award-number":["031A423A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031A423A"],"award-info":[{"award-number":["031A423A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite remarkable advances in therapeutic interventions, malignant melanoma (MM) remains a life-threating disease. Following high initial response rates to targeted kinase-inhibition metastases quickly acquire resistance and present with enhanced tumor progression and invasion, demanding alternative treatment options. We show 2<jats:sup>nd<\/jats:sup> generation hexameric TRAIL-receptor-agonist IZI1551 (IZI) to effectively induce apoptosis in MM cells irrespective of the intrinsic BRAF\/NRAS mutation status. Conditioning to the EC<jats:sub>50<\/jats:sub> dose of IZI converted the phenotype of IZI-sensitive parental MM cells into a fast proliferating and invasive, IZI-resistant metastasis. Mechanistically, we identified focal adhesion kinase (FAK) to play a dual role in phenotype-switching. In the cytosol, activated FAK triggers survival pathways in a PI3K- and MAPK-dependent manner. In the nucleus, the FERM domain of FAK prevents activation of <jats:italic>wt<\/jats:italic>p53, as being expressed in the majority of MM, and consequently intrinsic apoptosis. Caspase-8-mediated cleavage of FAK as well as FAK knockdown, and pharmacological inhibition, respectively, reverted the metastatic phenotype-switch and restored IZI responsiveness. FAK inhibition also re-sensitized MM cells isolated from patient metastasis that had relapsed from targeted kinase inhibition to cell death, irrespective of the intrinsic BRAF\/NRAS mutation status. Hence, FAK-inhibition alone or in combination with 2nd generation TRAIL-receptor agonists may be recommended for treatment of initially resistant and relapsed MM, respectively.<\/jats:p>","DOI":"10.1038\/s41419-022-04502-8","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T14:04:15Z","timestamp":1641996255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Greta","family":"Del Mistro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamala","family":"Riemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Kontermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Ginolhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-1254","authenticated-orcid":false,"given":"Rashi","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Presta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-3027","authenticated-orcid":false,"given":"Lasse","family":"Sinkkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-0548","authenticated-orcid":false,"given":"Dagmar","family":"Kulms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"4502_CR1","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-16-0064","volume":"22","author":"H Niessner","year":"2016","unstructured":"Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, et al. PI3K Pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res. 2016;22:5818\u201328.","journal-title":"Clin Cancer Res"},{"key":"4502_CR2","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1158\/1078-0432.CCR-17-0098","volume":"23","author":"H Niessner","year":"2017","unstructured":"Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, et al. BRAF inhibitors amplify the proapoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma. Clin Cancer Res. 2017;23:6203\u201314.","journal-title":"Clin Cancer Res"},{"key":"4502_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbamcr.2016.01.025","volume":"1863","author":"J Paluncic","year":"2016","unstructured":"Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, et al. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863:770\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"4502_CR4","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/annonc\/mdz221","volume":"30","author":"GV Long","year":"2019","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de BF, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2019;30:1848.","journal-title":"Ann Oncol"},{"key":"4502_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"4502_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"4502_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan PD, Arance A. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26:1557\u201363.","journal-title":"Nat Med"},{"key":"4502_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000258","volume":"42","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, et al. Clinical correlates of response to anti-PD-1-based therapy in patients with metastatic melanoma. J Immunother. 2019;42:221\u20137.","journal-title":"J Immunother"},{"key":"4502_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fmed.2018.00307","volume":"5","author":"RJ Ju","year":"2018","unstructured":"Ju RJ, Stehbens SJ, Haass NK. The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasis. Front Med. 2018;5:307.","journal-title":"Front Med"},{"key":"4502_CR10","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1242\/jcs.03098","volume":"119","author":"JD Humphries","year":"2006","unstructured":"Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006;119:3901\u20133.","journal-title":"J Cell Sci"},{"key":"4502_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrc727","volume":"2","author":"JD Hood","year":"2002","unstructured":"Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91\u2013100.","journal-title":"Nat Rev Cancer"},{"key":"4502_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tcb.2004.03.011","volume":"14","author":"NO Carragher","year":"2004","unstructured":"Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004;14:241\u20139.","journal-title":"Trends Cell Biol"},{"key":"4502_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347\u201367.","journal-title":"Cancer Cell"},{"key":"4502_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10555-007-9078-7","volume":"26","author":"AG Ramsay","year":"2007","unstructured":"Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007;26:567\u201378.","journal-title":"Cancer Metastasis Rev"},{"key":"4502_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015;63:114\u201328.","journal-title":"J Histochem Cytochem"},{"key":"4502_CR16","first-page":"690690","volume":"2015","author":"YL Tai","year":"2015","unstructured":"Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int. 2015;2015:690690.","journal-title":"Biomed Res Int"},{"key":"4502_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","volume":"63","author":"X Zhao","year":"2011","unstructured":"Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63:610\u20135.","journal-title":"Adv Drug Deliv Rev"},{"key":"4502_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2174\/187152011796817619","volume":"11","author":"VM Golubovskaya","year":"2011","unstructured":"Golubovskaya VM, Cance WG. FAK and p53 protein interactions. Anticancer Agents Med Chem. 2011;11:617\u20139.","journal-title":"Anticancer Agents Med Chem"},{"key":"4502_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2007.11.031","volume":"29","author":"ST Lim","year":"2008","unstructured":"Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29:9\u201322.","journal-title":"Mol Cell"},{"key":"4502_CR20","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/1535-7163.MCT-17-0551","volume":"16","author":"M Hutt","year":"2017","unstructured":"Hutt M, Marquardt L, Seifert O, Siegemund M, Muller I, Kulms D, et al. Superior properties of Fc-comprising scTRAIL fusion proteins. Mol Cancer Ther. 2017;16:2792\u2013802.","journal-title":"Mol Cancer Ther"},{"key":"4502_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24450-8","volume":"8","author":"M Siegemund","year":"2018","unstructured":"Siegemund M, Schneider F, Hutt M, Seifert O, Muller I, Kulms D, et al. IgG-single-chain TRAIL fusion proteins for tumour therapy. Sci Rep. 2018;8:7808.","journal-title":"Sci Rep"},{"key":"4502_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-018-0075-y","volume":"4","author":"MG Del","year":"2018","unstructured":"Del MG, Lucarelli P, Muller I, De LS, Zinoveva A, Hutt M, et al. Systemic network analysis identifies XIAP and IkappaBalpha as potential drug targets in TRAIL resistant BRAF mutated melanoma. NPJ Syst Biol Appl. 2018;4:39.","journal-title":"NPJ Syst Biol Appl"},{"key":"4502_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.molcel.2017.01.022","volume":"65","author":"CM Henry","year":"2017","unstructured":"Henry CM, Martin SJ. Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory \u201cFADDosome\u201d Complex upon TRAIL stimulation. Mol Cell. 2017;65:715\u201329.","journal-title":"Mol Cell"},{"key":"4502_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.249","volume":"4","author":"H Vorsmann","year":"2013","unstructured":"Vorsmann H, Groeber F, Walles H, Busch S, Beissert S, Walczak H, et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis. 2013;4:e719.","journal-title":"Cell Death Dis"},{"key":"4502_CR25","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"4502_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02264-8","volume":"22","author":"R Ietswaart","year":"2021","unstructured":"Ietswaart R, Gyori BM, Bachman JA, Sorger PK, Churchman LS. GeneWalk identifies relevant gene functions for a biological context using network representation learning. Genome Biol. 2021;22:55.","journal-title":"Genome Biol"},{"key":"4502_CR27","doi-asserted-by":"publisher","first-page":"16309","DOI":"10.1074\/jbc.275.21.16309","volume":"275","author":"Y Sonoda","year":"2000","unstructured":"Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem. 2000;275:16309\u201315.","journal-title":"J Biol Chem"},{"key":"4502_CR28","doi-asserted-by":"crossref","unstructured":"Li K, van Delft MF, Dewson G. Too much death can kill you: inhibiting intrinsic apoptosis to treat disease. EMBO J. 2021;40:e107341.","DOI":"10.15252\/embj.2020107341"},{"key":"4502_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nature24040","volume":"550","author":"H Lu","year":"2017","unstructured":"Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 2017;550:133\u20136.","journal-title":"Nature"},{"key":"4502_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/2159-8290.CD-15-0933","volume":"6","author":"MA Miller","year":"2016","unstructured":"Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, et al. Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance. Cancer Discov. 2016;6:382\u201399.","journal-title":"Cancer Discov"},{"key":"4502_CR31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nm.4155","volume":"22","author":"CH Shen","year":"2016","unstructured":"Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, et al. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med. 2016;22:1056\u201361.","journal-title":"Nat Med"},{"key":"4502_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11060-015-1761-x","volume":"123","author":"DA Wattson","year":"2015","unstructured":"Wattson DA, Sullivan RJ, Niemierko A, Merritt RM, Lawrence DP, Oh KS, et al. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. J Neurooncol. 2015;123:75\u201384.","journal-title":"J Neurooncol"},{"key":"4502_CR33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/onc.2012.164","volume":"32","author":"LY Dimberg","year":"2013","unstructured":"Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013;32:1341\u201350.","journal-title":"Oncogene"},{"key":"4502_CR34","doi-asserted-by":"publisher","first-page":"4576.","DOI":"10.3390\/ijms21134576","volume":"21","author":"AM Czarnecka","year":"2020","unstructured":"Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. Int J Mol Sci. 2020;21:4576.","journal-title":"Int J Mol Sci"},{"key":"4502_CR35","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1101\/gad.329771.119","volume":"33","author":"F Rambow","year":"2019","unstructured":"Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33:1295\u2013318.","journal-title":"Genes Dev"},{"key":"4502_CR36","first-page":"503","volume":"24","author":"VM Golubovskaya","year":"2009","unstructured":"Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer. Histol Histopathol. 2009;24:503\u201310.","journal-title":"Histol Histopathol"},{"key":"4502_CR37","doi-asserted-by":"publisher","first-page":"645.","DOI":"10.3390\/cancers13040645","volume":"13","author":"DC Rigiracciolo","year":"2021","unstructured":"Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, et al. Focal adhesion kinase fine tunes multifaced signals toward breast cancer progression. Cancers. 2021;13:645.","journal-title":"Cancers"},{"key":"4502_CR38","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3892\/etm.2015.2745","volume":"10","author":"D Kong","year":"2015","unstructured":"Kong D, Chen F, Sima NI. Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase\/Akt pathway. Exp Ther Med. 2015;10:1725\u201331.","journal-title":"Exp Ther Med"},{"key":"4502_CR39","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1073\/pnas.1107807108","volume":"108","author":"M Schober","year":"2011","unstructured":"Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin\/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci USA. 2011;108:10544\u201349.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4502_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1053\/gast.2001.20879","volume":"120","author":"J Grossmann","year":"2001","unstructured":"Grossmann J, Artinger M, Grasso AW, Kung HJ, Scholmerich J, Fiocchi C, et al. Hierarchical cleavage of focal adhesion kinase by caspases alters signal transduction during apoptosis of intestinal epithelial cells. Gastroenterology 2001;120:79\u201388.","journal-title":"Gastroenterology"},{"key":"4502_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1006\/gyno.2002.6632","volume":"85","author":"H Sasaki","year":"2002","unstructured":"Sasaki H, Kotsuji F, Tsang BK. Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein. Gynecol Oncol. 2002;85:339\u201350.","journal-title":"Gynecol Oncol"},{"key":"4502_CR42","first-page":"1915","volume":"62","author":"W Wick","year":"2002","unstructured":"Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 2002;62:1915\u20139.","journal-title":"Cancer Res"},{"key":"4502_CR43","doi-asserted-by":"publisher","first-page":"26056","DOI":"10.1074\/jbc.272.41.26056","volume":"272","author":"LP Wen","year":"1997","unstructured":"Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem. 1997;272:26056\u201361.","journal-title":"J Biol Chem"},{"key":"4502_CR44","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1128\/MCB.24.10.4361-4371.2004","volume":"24","author":"E Kurenova","year":"2004","unstructured":"Kurenova E, Xu LH, Yang X, Baldwin AS Jr., Craven RJ, Hanks SK, et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol. 2004;24:4361\u201371.","journal-title":"Mol Cell Biol"},{"key":"4502_CR45","doi-asserted-by":"publisher","first-page":"13328","DOI":"10.1074\/jbc.274.19.13328","volume":"274","author":"B van de Water","year":"1999","unstructured":"van de Water B, Nagelkerke JF, Stevens JL. Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells. J Biol Chem. 1999;274:13328\u201337.","journal-title":"J Biol Chem"},{"key":"4502_CR46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.molcel.2019.12.023","volume":"77","author":"I Muller","year":"2020","unstructured":"Muller I, Strozyk E, Schindler S, Beissert S, Oo HZ, Sauter T, et al. Cancer cells employ nuclear Caspase-8 to overcome the p53-dependent G2\/M checkpoint through cleavage of USP28. Mol Cell. 2020;77:970\u201384.","journal-title":"Mol Cell"},{"key":"4502_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molcel.2019.11.009","volume":"77","author":"MR Webster","year":"2020","unstructured":"Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, et al. Paradoxical role for wild-type p53 in driving therapy resistance in melanoma. Mol Cell. 2020;77:633\u201344.","journal-title":"Mol Cell"},{"key":"4502_CR48","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/nar\/gky1240","volume":"47","author":"D Gerard","year":"2019","unstructured":"Gerard D, Schmidt F, Ginolhac A, Schmitz M, Halder R, Ebert P, et al. Temporal enhancer profiling of parallel lineages identifies AHR and GLIS1 as regulators of mesenchymal multipotency. Nucleic Acids Res. 2019;47:1141\u201363.","journal-title":"Nucleic Acids Res"},{"key":"4502_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12688\/f1000research.29032.2","volume":"10","author":"F Molder","year":"2021","unstructured":"Molder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al. Sustainable data analysis with Snakemake. F1000Res. 2021;10:33.","journal-title":"F1000Res"},{"key":"4502_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-016-1900-2","volume":"9","author":"M Schubert","year":"2016","unstructured":"Schubert M, Lindgreen S, Orlando L. AdapterRemoval v2: rapid adapter trimming, identification, and read merging. BMC Res Notes. 2016;9:88.","journal-title":"BMC Res Notes"},{"key":"4502_CR51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"4502_CR52","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkz114","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47.","journal-title":"Nucleic Acids Res"},{"key":"4502_CR53","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2019","unstructured":"Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 2019;35:2084\u201392.","journal-title":"Bioinformatics"},{"key":"4502_CR54","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016;32:2847\u20139.","journal-title":"Bioinformatics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04502-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:58:10Z","timestamp":1669301890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["4502"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04502-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The usage of patient material (metastasis) for biochemical analysis was approved by the ethics committee of the TU-Dresden (EK 335082018) and informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"54"}}